Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 121

1.

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer.

Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE.

Br J Cancer. 2011 Jun 7;104(12):1828-35. doi: 10.1038/bjc.2011.156. Epub 2011 May 10.

PMID:
21559012
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.

Munster PN, Marchion D, Thomas S, Egorin M, Minton S, Springett G, Lee JH, Simon G, Chiappori A, Sullivan D, Daud A.

Br J Cancer. 2009 Oct 6;101(7):1044-50. doi: 10.1038/sj.bjc.6605293. Epub 2009 Sep 8.

PMID:
19738609
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.

Mackay HJ, Hirte H, Colgan T, Covens A, MacAlpine K, Grenci P, Wang L, Mason J, Pham PA, Tsao MS, Pan J, Zwiebel J, Oza AM.

Eur J Cancer. 2010 Jun;46(9):1573-9. doi: 10.1016/j.ejca.2010.02.047. Epub 2010 Mar 19.

PMID:
20304628
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes.

Sharma D, Saxena NK, Davidson NE, Vertino PM.

Cancer Res. 2006 Jun 15;66(12):6370-8.

PMID:
16778215
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer.

Trinh XB, Sas L, Van Laere SJ, Prové A, Deleu I, Rasschaert M, Van de Velde H, Vinken P, Vermeulen PB, Van Dam PA, Wojtasik A, De Mesmaeker P, Tjalma WA, Dirix LY.

Oncol Rep. 2012 Mar;27(3):657-63. doi: 10.3892/or.2011.1562. Epub 2011 Nov 24.

PMID:
22134540
[PubMed - indexed for MEDLINE]
6.

Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.

Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaëth D, Legouffe E, Allouache D, El Kouri C, Pujade-Lauraine E.

J Clin Oncol. 2012 Aug 1;30(22):2718-24. doi: 10.1200/JCO.2011.39.0708. Epub 2012 May 7.

PMID:
22565002
[PubMed - indexed for MEDLINE]
7.

The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen.

Jang ER, Lim SJ, Lee ES, Jeong G, Kim TY, Bang YJ, Lee JS.

Oncogene. 2004 Mar 4;23(9):1724-36.

PMID:
14676837
[PubMed - indexed for MEDLINE]
8.
9.

Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.

Blumenschein GR Jr, Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL, Chiao JH, Chen C, Frankel SR.

Invest New Drugs. 2008 Feb;26(1):81-7. Epub 2007 Oct 25.

PMID:
17960324
[PubMed - indexed for MEDLINE]
10.

Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.

Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, Reilly JF, Loboda A, Nebozhyn M, Fantin VR, Richon VM, Scheithauer B, Giannini C, Flynn PJ, Moore DF Jr, Zwiebel J, Buckner JC.

J Clin Oncol. 2009 Apr 20;27(12):2052-8. doi: 10.1200/JCO.2008.19.0694. Epub 2009 Mar 23. Erratum in: J Clin Oncol. 2009 Jul 1;27(19):3262-3.

PMID:
19307505
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.

Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, Loboda A, Fantin VR, Randolph SS, Hardwick JS, Reilly JF, Chen C, Ricker JL, Secrist JP, Richon VM, Frankel SR, Kantarjian HM.

Blood. 2008 Feb 1;111(3):1060-6. Epub 2007 Oct 25.

PMID:
17962510
[PubMed - indexed for MEDLINE]
Free Article
12.

LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.

Goel S, Sharma R, Hamilton A, Beith J.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD004562. doi: 10.1002/14651858.CD004562.pub4. Review.

PMID:
19821328
[PubMed - indexed for MEDLINE]
13.

High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment.

Kvinnsland S, Anker G, Dirix LY, Bonneterre J, Prove AM, Wilking N, Lobelle JP, Mariani O, di Salle E, Polli A, Massimini G.

Eur J Cancer. 2000 May;36(8):976-82.

PMID:
10885600
[PubMed - indexed for MEDLINE]
14.

A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy.

Wilson PM, El-Khoueiry A, Iqbal S, Fazzone W, LaBonte MJ, Groshen S, Yang D, Danenberg KD, Cole S, Kornacki M, Ladner RD, Lenz HJ.

Cancer Chemother Pharmacol. 2010 Apr;65(5):979-88. doi: 10.1007/s00280-009-1236-x.

PMID:
20062993
[PubMed - indexed for MEDLINE]
15.

Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.

Barone I, Brusco L, Gu G, Selever J, Beyer A, Covington KR, Tsimelzon A, Wang T, Hilsenbeck SG, Chamness GC, Andò S, Fuqua SA.

J Natl Cancer Inst. 2011 Apr 6;103(7):538-52. doi: 10.1093/jnci/djr058. Epub 2011 Mar 29.

PMID:
21447808
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Tipifarnib plus tamoxifen in tamoxifen-resistant metastatic breast cancer: a negative phase II and screening of potential therapeutic markers by proteomic analysis.

Dalenc F, Doisneau-Sixou SF, Allal BC, Marsili S, Lauwers-Cances V, Chaoui K, Schiltz O, Monsarrat B, Filleron T, Renée N, Malissein E, Meunier E, Favre G, Roché H.

Clin Cancer Res. 2010 Feb 15;16(4):1264-71. doi: 10.1158/1078-0432.CCR-09-1192. Epub 2010 Feb 9.

PMID:
20145184
[PubMed - indexed for MEDLINE]
Free Article
17.

Activity and safety of the antiestrogen EM-800, the orally active precursor of acolbifene, in tamoxifen-resistant breast cancer.

Labrie F, Champagne P, Labrie C, Roy J, Laverdière J, Provencher L, Potvin M, Drolet Y, Pollak M, Panasci L, L'Espérance B, Dufresne J, Latreille J, Robert J, Samson B, Jolivet J, Yelle L, Cusan L, Diamond P, Candas B.

J Clin Oncol. 2004 Mar 1;22(5):864-71.

PMID:
14990642
[PubMed - indexed for MEDLINE]
18.

Fulvestrant in advanced breast cancer following tamoxifen and aromatase inhibition: a single center experience.

Wang J, Jain S, Coombes CR, Palmieri C.

Breast J. 2009 May-Jun;15(3):247-53. doi: 10.1111/j.1524-4741.2009.00713.x.

PMID:
19645779
[PubMed - indexed for MEDLINE]
19.

Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.

Michaud LB, Buzdar AU.

Drugs Aging. 2000 Apr;16(4):261-71. Review.

PMID:
10874521
[PubMed - indexed for MEDLINE]
20.

Histone deacetylase (HDAC) 1 and 2 expression and chemotherapy in gastric cancer.

Mutze K, Langer R, Becker K, Ott K, Novotny A, Luber B, Hapfelmeier A, Göttlicher M, Höfler H, Keller G.

Ann Surg Oncol. 2010 Dec;17(12):3336-43. doi: 10.1245/s10434-010-1182-1. Epub 2010 Jun 29.

PMID:
20585871
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk